CHEETAH MEDICAL INTRODUCES STARLING SV NONINVASIVE HEMODYNAMIC MONITORING SYSTEM
Dynamic IV fluid-assessment using the newly introduced Starling™ SV and the benchmark CHEETAH NICOM™ systems are the only way to know noninvasively and in real-time whether a patient will be helped or potentially harmed by additional IV fluids.
“No matter the site of care or the clinical challenge, effective hemodynamic measurement and management is integral to achieving an optimal clinical outcome,” said Douglas Hansell, M.D., Chief Physician Executive for Cheetah Medical. “Approximately 50 percent of hospitalized patients are at risk of hemodynamic overload.2 Until the introduction of CHEETAH NICOM™, the only choices for obtaining accurate and continuous hemodynamic measurements were invasive technologies that carry their own set of risks. Now, with the Starling SV or CHEETAH NICOM, a clinician has all of the important parameters continuously at his or her disposal. Clinical status and the effect of IV fluids can be monitored at any time and treatment modified accordingly.”
The expansion of Cheetah medical’s product line comes on the heels of results in three major clinical trials (ProCESS, ProMISE, ARISE), as well as updated sepsis guidelines by the following organizations — Surviving Sepsis Campaign, National Quality Forum(NQF), Centers for Medicare & Medicaid Services (CMS) and European Society of Intensive Care Medicine (ESICM)3,4,5 — all of whom updated their guidance to include dynamic measures of fluid responsiveness for patients with severe sepsis or septic shock.
IV-fluid responsiveness is also a major component of Enhanced Recovery After Surgery (ERAS), which is showing improved clinical outcomes for surgical patients. “The FDA-cleared and CE-marked CHEETAH hemodynamic monitoring systems are uniquely designed and strongly positioned as the solution for completely noninvasive and continuous IV-fluid assessment in the operating room or a critical care setting,” said Chris Hutchison, President and CEO of Cheetah Medical.
The Starling SV system has a sensitivity of 94% and specificity of 100% for predicting IV-fluids responsiveness in critical care situations6. The noninvasive Starling SV system predicts IV-fluids responsiveness similarly to invasive esophageal Doppler and other invasive modalities5. In addition to predicting fluid responsiveness, Starling SV is one of the few technologies that allows clinicians to directly monitor the change in cardiac stroke volume with therapy. Starling SV may assist in reducing hospital length of stay (LOS)7.
Starling™ SV Benefits Summarized:
- 100% noninvasive, easy to use, with no patient discomfort.
- Eliminates risk of infection and vascular damage associated with older, invasive technologies requiring arterial or central lines.
- Independently validated against pulmonary artery catheter.
- Accuracy not affected by vasopressors, inotropes, and shock states.
- EMR-compatible, with the ability to establish a time-stamped patient record for documentation.
- Provides continuous information on Cardiac Index, Cardiac Output, StrokeVolume Index, Stroke Volume, Total Peripheral Resistance, and other vitally important parameters.
Click here for more information on the Starling SV hemodynamic monitoring system
About Cheetah Medical
Cheetah Medical is the leading company in the noninvasive hemodynamic monitoring market segment. Headquartered in Newton, Mass., and approved in 60 countries including the U.S., Cheetah Medical is a rapidly growing medical device company with a breakthrough technology, Bioreactance®, designed to set a new standard of care for noninvasive, beat-to-beat, user- and patient-friendly cardiac output monitoring. Bioreactance technology has been proven to be faster and more accurate in comparison to the standard invasive technologies such as the pulmonary artery catheter and esophageal Doppler. Cheetah Medical’s systems have met with success in critical care patients who are being IV-fluid resuscitated to manage sepsis and in trauma patients who have experienced high fluid loss. To learn more, please visit www.cheetah-medical.com.
1 The global hemodynamic monitoring systems market is expected to reach $1.1074 billion by 2019, according to MarketsandMarkets; Cheetah’s growth currently exceeds the CAGR of 4.5% forecast for the same period.
2 Marik PE, et al. Hemodynamic parameters to guide fluid therapy. Ann of Intensive Care 2011; 1:1.
5 Cecconi M, Backer DD, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. 2014
6 Marik PE, et al. Chest, 2013.
7 Dunham et al. J Trauma Acute Care Surg, 2012